ALRUD advised a shareholder of Veropharm on the sale of shares to Abbot

ALRUD advised a shareholder of Veropharm, one of the Russian leading pharmaceutical manufacturers with a portfolio of more than 100 pharmaceuticals, on the sale of shares to the US company Abbot, which works to develop the healthcare industry in Russia and around the world and aims to ensure reliable supplies of medical products to Russian patients.

As a result of this deal, Abbott acquired a portfolio of products that align well with the company’s priority therapeutic businesses such as women’s health, cardiology, gastroenterology, and a range of oncology products.

The transaction was valued at approximately US$500m and was the largest Russian pharmaceutical M&A transaction in 2014.

The ALRUD team that worked on the project under the leadership of Alexander Zharskiy (Partner and Head of Corporate and M&A Practice) included representatives of the Corporate Practice: Counsel Oleg Ezhov and Associate Irina Kuyantseva.